Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Clinicaltrials.gov identifier recruitment status First Posted Last update posted
NCT03430011 Recruiting February 12, 2018 August 11, 2020

study description
Brief Summary

This is an open-label, multicenter, Phase 1/2 study to determine the safety and efficacy of JCARH125, a CAR T-cell product that targets B-cell maturation antigen (BCMA), in adult subjects with relapsed and/or refractory multiple myeloma. The study will include a Phase 1 part to determine the recommended dose of JCARH125 in subjects with relapsed and/or refractory multiple myeloma, followed by a Phase 2 part to further evaluate the safety and efficacy of JCARH125 at the recommended dose. The safety and tolerability of JCARH125 in subjects who receive prophylactic treatment with anakinra will be evaluated in a separate Phase 1 cohort. The antitumor activity of JCARH125 in subjects who have been previously treated with BCMA-directed therapy will be evaluated in separate Phase 2a cohorts.

Condition or Disease: Multiple Myeloma
Intervention/treatment: Biological: JCARH125
Biological: JCARH125 + anakinra
Phase: Phase 1/Phase 2
Detailed Description

N/A


study design
Study Type: Interventional
Estimated Enrollment : 245 participants
Intervention Model : Single Group Assignment
Masking: None (Open Label) ()
Primary Purpose: Treatment
Official Title: Protocol H125001: An Open-Label Phase 1/2 Study of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory Multiple Myeloma
Actual Study Start Date: February 2018
Estimated Primary Completion Date: January 2022
Estimated Study Completion Date: June 2023

Arms and interventions
Arm Intervention/treatment
Experimental: JCARH125
Subjects will receive a course of lymphodepleting chemotherapy with fludarabine and cyclophosphamide followed by a single dose of JCARH125
Biological: JCARH125
Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCARH125. During JCARH125 production, participants may receive bridging chemotherapy for disease control. Following successful generation of JCARH125 product, participants will receive a course of lymphodepleting chemotherapy followed by one dose of JCARH125 administered intravenously (IV).
Experimental: JCARH125 + anakinra
Subjects will receive a course of lymphodepleting chemotherapy with fludarabine and cyclophosphamide followed by prophylactic treatment with anakinra and a single dose of JCARH125
Biological: JCARH125 + anakinra
Participants will undergo leukapheresis to isolate PBMCs for the production of JCARH125. During JCARH125 production, participants may receive bridging chemotherapy for disease control. Following successful generation of JCARH125 product, participants will receive a course of lymphodepleting chemotherapy followed by two doses of anakinra administered subcutaneously and one dose of JCARH125 administered IV. Subjects receive anakinra for 5 consecutive days following JCARH125 infusion.
outcome measures
Primary Outcome Measures: 1. Phase 1: Incidence and severity of adverse events [ Time Frame: 2 years ]
Proportion of subjects with adverse events overall and by severity grade
2. Phase 1: Incidence of dose-limiting toxicities (DLTs) [ Time Frame: 21 days ]
Proportion of subjects with adverse events meeting DLT criteria
3. Phase 1: Incidence and severity of clinically significant laboratory abnormalities [ Time Frame: 2 years ]
Proportion of subjects with clinically significant laboratory abnormalities overall and by severity grade
4. Phase 1 Anakinra Cohort only: Incidence and severity of Grade 2 or higher cytokine release syndrome (CRS) [ Time Frame: 2 years ]
Proportion of subjects with Grade 2 or higher CRS
5. Phase 1 Anakinra Cohort only: Percentage of subjects with no CRS on Days 1, 2, or 3 following JCARH125 infusion [ Time Frame: 2 years ]
Proportion of subjects with no CRS on Days 1, 2, or 3 following JCARH125 infusion
6. Phase 1 Anakinra Cohort only: Time to onset of Grade 2 or higher CRS [ Time Frame: 2 years ]
Median time to onset of Grade 2 or higher CRS
7. Phase 2: Overall response rate [ Time Frame: 2 years ]
Proportion of subjects with a partial response or better by International Myeloma Working Group (IMWG) criteria
Secondary Outcome Measures: 1. Phase 1 and Phase 2: Maximum concentration (Cmax) of JCARH125 in the blood [ Time Frame: 2 years ]
2. Phase 1 and Phase 2: Time to maximum concentration (Tmax) of JCARH125 in the blood [ Time Frame: 2 years ]
3. Phase 1 and Phase 2: Area under the concentration vs time curve (AUC) of JCARH125 in the blood [ Time Frame: 2 years ]
4. Phase 1 and Phase 2: Duration of persistence of JCARH125 CAR T cells in the blood [ Time Frame: 2 years ]
5. Phase 1: Overall response rate [ Time Frame: 2 years ]
Proportion of subjects with a partial response (PR) or better by IMWG criteria
6. Phase 1 and Phase 2: Complete response (CR) rate [ Time Frame: 2 years ]
Proportion of subjects with a CR by IMWG criteria
7. Phase 2: Duration of response [ Time Frame: 2 years ]
Time from first response (stringent complete response [sCR], CR, very good partial response [VGPR], or PR) to the earlier date of progressive disease (PD) or death due to any cause
8. Phase 2: Duration of CR [ Time Frame: 2 years ]
Time from first sCR or CR to the earlier date of PD or death due to any cause
9. Phase 2: incidence and severity of adverse events [ Time Frame: 2 years ]
Proportion of subjects with adverse events overall and by severity grade
10. Phase 2: Incidence and severity of clinically significant laboratory abnormalities [ Time Frame: 2 years ]
Proportion of subjects with clinically significant laboratory abnormalities overall and by severity grade
11. Phase 2: Overall survival [ Time Frame: 2 years ]
Time from JCARH125 infusion until death
12. Phase 2: Progression-free survival [ Time Frame: 2 years ]
Time from JCARH125 infusion until the earliest of date of death or disease progression as assessed by IMWG criteria
13. Phase 2: Time to response [ Time Frame: 2 years ]
Time from JCARH125 infusion to first documentation of PR or better
14. Phase 2: Time to CR [ Time Frame: 2 years ]
Time from JCARH125 infusion to first documentation of CR or better
15. Phase 2 (excluding Phase 2a): Changes in measures of health-related quality of life (HRQoL) [ Time Frame: 2 years ]
Change from baseline in HRQoL
16. Phase 2 (excluding Phase 2a): Numbers of days in the intensive care unit (ICU) [ Time Frame: 2 years ]
17. Phase 2 (excluding Phase 2a): Number of non-ICU inpatient days [ Time Frame: 2 years ]

Eligibility Criteria
Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Criteria

Key Inclusion Criteria:

1. Diagnosis of multiple myeloma (MM) with relapsed and/or refractory (R/R) disease. Participants must have received at least 3 prior anti-myeloma treatment regimens. Participants must have previously received all of the following therapies and must be refractory to the last line of therapy prior to entering the study (not applicable to Phase 2a):

1. Autologous stem cell transplant

2. A regimen that included an immunomodulatory agent (eg, thalidomide, lenalidomide, pomalidomide) and a proteasome inhibitor (eg, bortezomib, carfilzomib, ixazomib), either alone or in combination

3. Anti-CD38 (eg, daratumumab) as part of a combination regimen or as a monotherapy

Subjects who have received prior allogeneic stem cell transplant or donor lymphocyte infusion at least 100 days before enrollment with no signs of acute or chronic graft-versus-host disease (GVHD) will be considered eligible. Subjects who were not candidates to receive one or more of the above treatments (ie, contraindicated) are eligible.

2. Subjects must have measurable disease.

3. Subject must be willing to provide fresh bone marrow biopsy samples during Screening (and prior to study treatment, if required).

4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

5. Adequate renal, bone marrow, hepatic, pulmonary, and cardiac function

6. Phase 2a cohorts only - Subjects with R/R MM who have been previously treated with prior BCMA-directed anti-myeloma therapy, achieved at least a partial response (PR) and progressed on the following treatment:

1. Subjects who have received prior BCMA-directed CAR T-cell therapy. The last CAR T-cell therapy must have been received at least 6 months prior to JCARH125 screening.

2. Subjects who have received prior BCMA-directed T-cell engager therapy.

3. Subjects who have received prior BCMA-directed antibody-drug conjugate therapy.

Exclusion Criteria:

1. Subjects with known active or history of CNS involvement by malignancy

2. Subjects with solitary plasmacytoma; active or history of plasma cell leukemia (PCL); Waldenstrom's macroglobulinemia; Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal plasmaproliferative disorder, Skin changes (POEMS) syndrome; or symptomatic amyloidosis

3. Subjects who are considered eligible to receive and have not refused an autologous stem cell transplant

4. History of another primary malignancy that has not been in remission for at least 3 years. The following are exempt from the 3-year limit: non-melanoma skin cancer, curatively treated localized prostate cancer, cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on Pap smear, and in situ breast cancer that has been completely resected.

5. Require systemic immunosuppressive therapies (eg, calcineurin inhibitors, methotrexate, mycophenolate, rapamycin, thalidomide, immunosuppressive antibodies such as anti-IL-6 or anti-IL-6 receptor [IL-6R])

6. Prior CAR T-cell or other genetically-modified T-cell therapy (not applicable for subjects enrolled in Phase 2a cohorts)

7. Prior treatment with a BCMA-targeted agent (not applicable for subjects enrolled in Phase 2a cohorts)

8. History or presence of clinically relevant CNS pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis

9. Untreated or active infection at time of initial screening, at the time of leukapheresis, within 72 hrs before lymphodepletion, or 5 days before JCARH125 infusion.

10. History of any of the following cardiovascular conditions within 6 months of screening: Class III or IV heart failure as defined by the New York Heart Association (NYHA), myocardial infarction, unstable angina, uncontrolled or symptomatic atrial arrhythmias, any ventricular arrhythmias, or other clinically significant cardiac disease

11. Subjects with known hypersensitivity to E Coli-derived proteins (only applicable to subjects in Phase 1 Anakinra Cohort)

12. History of severe immediate hypersensitivity reaction to any of the protocol-mandated or recommended agents used in this study


Contacts and Locations
Contacts

Contact:

Locations
United States, Alabama University of Alabama Birmingham
United States, California City of Hope Comprehensive Cancer Center Duarte
United States, California University of California, Los Angeles Los Angeles
United States, California University of California San Francisco
United States, Colorado SCRI - Colorado Blood Cancer Institute Denver
United States, Georgia Winship Cancer Institute at Emory University Atlanta
United States, Illinois The University of Chicago Medicine Chicago
United States, Kansas Kansas University Medical Center Westwood
United States, Maryland Johns Hopkins Hospital Baltimore
United States, Massachusetts Massachusetts General Hospital Boston
United States, Michigan Karmanos Cancer Institute Wayne State Detroit
United States, Minnesota Mayo Clinic Rochester
United States, New Jersey Hackensack University Medical Center Hackensack
United States, New York Roswell Park Cancer Institute Buffalo
United States, New York Memorial Sloan Kettering Cancer Center New York
United States, Oregon Oregon Health & Science University Portland
United States, Texas SCRI - Texas San Antonio
United States, Washington Swedish Cancer Institute Seattle
United States, Washington Fred Hutchinson Cancer Research Center Seattle
United States, Wisconsin Froedtert Hospital Medical College Wisconsin Milwaukee
Sponsors and Collaborators
Juno Therapeutics, a Subsidiary of Celgene
Investigator
Study Director : Mariana Cota, MD Juno Therapeutics, Inc.
More Information
Responsible Party : Juno Therapeutics, a Subsidiary of Celgene
ClinicalTrials.gov Identifier : NCT03430011     
Other Study ID Numbers : H125001
First Posted : February 12, 2018
Last Update Posted : August 11, 2020
Last Verified : August 2020
Individual Participant
Data (IPD) Sharing
Statement:
 
Plan to Share IPD: Undecided
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Juno Therapeutics, a Subsidiary of Celgene: JCARH125
multiple myeloma
CAR T cells
B-cell maturation antigen
BCMA
autologous T-cell therapy
immunotherapy
chimeric antigen receptor
Additional relevant MeSH terms :
Multiple Myeloma
Neoplasms, Plasma Cell